Urogen Pharma Ltd
NASDAQ:URGN
Urogen Pharma Ltd
UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Launch momentum: Permanent J-code effective Jan 1, 2026 removed a key barrier and management reports an acceleration in new/repeat prescribers, patient enrollment forms and new patient starts for ZUSDURI in early 2026.
Early commercial results: ZUSDURI net product revenue was $15.8 million in 2025 (Q3 $1.8M; Q4 $14M) while JELMYTO generated $94 million for the year; company total revenue was $109.8 million in 2025, up 21% year‑over‑year.
Clinical path and filings: UGN-103 showed a 77.8% complete response at 3 months in UTOPIA; company plans an NDA submission in H2 2026 with potential approval in 2027 and is considering lifecycle expansion into adjuvant and high‑grade settings.
Balance sheet strengthened: Refinance with Pharmakon provides a $200 million initial tranche (up to $250M facility with a $50M optional tranche), fixed 8.25% interest and later principal repayment start in 2030 — management says this increases financial flexibility without changing prior path‑to‑profitability commentary.
Guidance and costs: 2026 guidance: JELMYTO revenue $97M–$101M; total operating expenses $240M–$250M (includes $20M–$24M noncash share‑based comp). Company is not providing 2026 sales guidance for ZUSDURI yet.
Clinical durability and patient impact: ENVISION data for ZUSDURI: ~80% complete response at 3 months; Kaplan‑Meier ~80% disease‑free at 12 months and ~72% at 24 months; management highlights outpatient, nonsurgical 6‑dose regimen and strong anecdotal physician/patient acceptance.
Commercial execution focus: Company is scaling to reach ~8,500 target urologists, tracking conversion from patient enrollment form (PEF) to dosing (historical 45–60 days expected to compress toward 2–3 weeks over 2026), and sees shift from hospital toward community settings as permanent J-code normalizes access.
